Clinical predictor of survival following docetaxel‑based chemotherapy
Distance scaling for median PGA and median PSA at 0.05, 0.2 and 1.0 s... | Download Scientific Diagram
Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis | Prostate Cancer and Prostatic Diseases
TE and PSA levels changes. Values are mean±SD. a p | Download Scientific Diagram
Diagnostics | Free Full-Text | Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A ...
Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
Low detectable PSA after prostatectomy – watch or treat? | THE "NEW" PROSTATE CANCER INFOLINK
Single Subject Studies in Prostate Cancer: How graphing PSA test results and testosterone levels using Process Behavior and Celeration Charts can provide insight and guide clinical decisions
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET | Journal of Nuclear Medicine
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value | PLOS ONE
Third Generation PSA Assay
Table 5.5 from Prostate Specific Antigen (PSA) growth curves: A method to improve prostate cancer screening | Semantic Scholar
18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study | Journal of Nuclear Medicine
Comparision of mean ages, PSA levels and pre and post-treatment MPV... | Download Scientific Diagram
Murine Polyomavirus Virus-Like Particles Carrying Full-Length Human PSA Protect BALB/c Mice from Outgrowth of a PSA Expressing Tumor | PLOS ONE
PSA Anxiety | Dan's Journey through Prostate Cancer
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response | SpringerLink
Forest plot of ≥50% decline in PSA AA Antiandrogen, 95% CI 95%... | Download Scientific Diagram
